CN101988117A - In-situ hybridization detection reagent kit of CA242 gene, detection method and application thereof - Google Patents

Abstract

The invention relates to an in-situ hybridization detection reagent kit of a CA242 (cancer antigen) gene, which comprises a hybridization probe and a marker, wherein the sequence of the hybridization probe is shown in SEQ ID NO.1. The invention also provides an in-situ hybridization detection method of the CA242 gene. The kit provided in the invention has the characteristics of high sensitivity and strong specificity. The detection method is simple and convenient for operation, and can be generally used and popularized in hospitals above district level.

Description

A kind of hybridization in situ detection kit of CA242 gene and detection method thereof and application

[technical field]

The present invention relates to a kind of test kit, specifically about a kind of hybridization in situ detection kit and detection method and application of CA242 gene

[background technology]

Carcinoma of the pancreas has become one of ten big malignant tumours of China human mortality.Young carcinoma of the pancreas patient is also than the trend that was significantly increased before 10 years, and grade of malignancy is higher, and prognosis is poorer.With regard to the happening part of carcinoma of the pancreas, see at most with the head of pancreas position that still account for about 70%, body of pancreas takes second place, tail of pancreas portion more takes second place, and a body afterbody that has all has, and belongs to diffuse lesion or multicentricity pathology.At present, the pathogenic factor of carcinoma of the pancreas it be unclear that, and has found that some environmental factorss are relevant with the generation of carcinoma of the pancreas.Wherein fixed primary Hazard Factor are smoking.The carcinoma of the pancreas relative risk takes place the smoker is 1.5 times of non-smoker, and along with amount of smoking increases and increases.Other high-risk factors also have diabetes, chololithiasis, drink (comprising beer) and chronic pancreatitis etc.Take food higher fatty acid, high protein diet and purified flour foods, 20 years persons after the gastrectomy also are that risk factor for pancreatic cancer takes place.Carcinoma of the pancreas lethality extra-high-speed, how possibility surreptitious concealment because it is fallen ill has entered event in late period when making a definite diagnosis.

Large bowel cancer is the general name of the colorectal carcinoma and the rectum cancer, and large bowel cancer is meant the malignant change prognosis mala that big epithelium of intestinal mucosa takes place under multiple carcinogenic factor effects such as environment or heredity, and mortality ratio is higher.Large bowel cancer is the malignant tumour of big epithelium of intestinal mucosa origin.It is one of modal malignant tumor of digestive tract.Large bowel cancer gi tract common malignancy is only second to cancer of the stomach, the esophageal carcinoma.

Cancer antigen 242 (CA242) be find by the monoclonal antibody of anti-human large intestine cancer clone Co Lo205 and the CA50 co expression, but identification is a kind of sialylated sphingoglycolipid antigen that is different from tumor associated antigens such as CA 199 and CA125.The expression of CA242 antigenic determinant more has specificity in malignant tumour.CA242 can differentiate with benign liver and gall pancreas and gastrointestinal tract disease mainly as the tumor-marker of carcinoma of the pancreas and large bowel cancer.CA242mRNA will express Zao than CA242 albumen, with the method that detects gene than detect albumen more early stage, more clinical value arranged.CA242mRNA is the good indicator of carcinoma of the pancreas early diagnosis, and helps the differential diagnosis of carcinoma of the pancreas and biliary benign disease.In optimum gi system disease, CA242mRNA is not expressing.CA242mRNA and CEA mRNA joint-detection, it is early stage or shift early stage diagnostic sensitivity to improve large bowel cancer.Other malignant tumour (CA242mRNA such as ovarian cancer, uterus carcinoma, lung cancer and tumor of head and neck express and also increase).

Along with molecular biotechnology is perfect day by day, functional genomics, the deep expansion of research such as cancer genomics, so far, we might do more accurate early diagnosis on gene level, form the early prediction diagnosis that (during mono-clonal) just can accomplish gene level in canceration early stage or cancer cells.The present invention is with nucleic acid hybridization in situ technology for detection CA242 gene, and the diagnosis of carcinoma of the pancreas, digestive tract cancer and other cancer early gene level is had very important clinical meaning.CA242 gene order number: AY870819,329bp, RNA, CDS＜1..〉329.

Hybridization in situ technique of the present invention (in situ hybridization) combines molecular biology and cytochemistry technology, is probe with the nucleic acid molecule of mark, in the technology of histocyte in situ detection specific nucleic acid molecule.Its principle is to make the nucleic acid strand (being probe) that contains distinguished sequence, process mark, under optimum conditions with histocyte in the complementary nucleic acid strand be that target nucleic acid is hybridized, with radioautograph or immunocytochemistry label probe is surveyed again, thereby shown special DNA or RNA molecule at cell in-situ.

[summary of the invention]

The objective of the invention is provides a kind of purposes of hybridization in situ detection kit of CA242 gene at deficiency of the prior art.

One purpose more of the present invention is that a kind of hybridization in situ detection kit of CA242 gene is provided.

Another purpose of the present invention is that a kind of in situ hybridization detection method of CA242 gene is provided.

For achieving the above object, the technical scheme taked of the present invention is:

The application of a kind of hybridization in situ detection kit of CA242 gene in preparation detection carcinoma of the pancreas or large bowel cancer disease medicament, described test kit comprises hybridization probe, marker, described hybridization probe sequence is shown in SEQ ID NO.1.

The RNA sequence of described hybridization probe sequence shown in SEQ ID NO.1.

Described marker is selected from radionuclide or non-radioactive marker.

Described radionuclide is selected from ³H, ³⁵S, ¹²⁵I or ³²A kind of among the P.

Described non-radioactive marker is selected from a kind of in vitamin H, digoxin, alkaline phosphatase, horseradish peroxidase or the fluorescein.

Described non-radioactive marker is preferably from digoxin.

Described test kit also comprises synergistic agent, and described synergistic agent is the alkaline phosphatase enzyme antibody.

For realizing above-mentioned second purpose, the technical scheme that the present invention takes is:

A kind of hybridization in situ detection kit of CA242 gene comprises hybridization probe, marker, and wherein said hybridization probe sequence is shown in SEQ ID NO.1, and described marker is selected from radionuclide or non-radioactive marker.

For realizing above-mentioned the 3rd purpose, the technical scheme that the present invention takes is:

A kind of in situ hybridization detection method of CA242 gene, this method may further comprise the steps:

A, the hybridization probe in the test kit is contacted with RNA to be measured in the substrate, form hybridization complex;

The hybridization complex that b, detection a step obtain.

The condition that forms hybridization complex in the described a step is: the temperature of nucleic acid hybridization is 42 ℃; The time of nucleic acid hybridization is 16-24 hour, and described substrate is selected blood cell sample or histocyte sample for use.

The component of diagnostic kit of the present invention is by hybridization probe, hybridization solution, developer, compositions such as synergistic agent.The nucleic acid hybridization principle of this test kit is that the molecular biology insider all knows, and the concrete operations step is to carry out quantitative analysis, result's report under sample disposal, prehybridization, hybridization, immunohistochemical staining, the mirror, and wherein Za Jiao concrete steps comprise:

Instrumentation:

1). sample to be measured is put into reactive tank;

2). instrument discards liquid automatically, adds Digestive system automatically;

3). instrument discards liquid automatically, and the back is fixing automatically;

4). instrument discards liquid automatically, automatically prehybridization (42 ℃);

5). instrument discards liquid automatically, cleans automatically;

6). instrument discards liquid automatically, automatically hybridization (42 ℃);

7). instrument discards liquid automatically, cleans automatically;

8). instrument discards liquid automatically, and automatic and DIG antibody is cultivated (room temperature);

9). instrument discards liquid automatically, cleans colour developing automatically;

10). take out the mounting microscopy.

The invention has the advantages that:

1, test kit provided by the invention has characteristics highly sensitive, high specificity.

2, detection method of the present invention is convenient and simple for operation, can be widely used and promoted in Municipal Hospitals.

3, clinical meaning of the present invention is that more early stage tracking detects carcinoma of the pancreas or large bowel cancer generation dynamic process, and the detection and the screening implement that are used for carcinoma of the pancreas or large bowel cancer preventive medicine.Diagnostic kit of the present invention is with other detects the oncofetal protein mark clinically, and the medical imaging inspection has remarkable difference.The present invention can detect the CA242 unconventionality expression on gene level, before medical imaging inspection and other inspection is not found occupancy carcinoma of the pancreas or large bowel cancer focus, before the cancer biochemical indicator does not produce unusually, also do not form before the lump, the information acquisition of above abnormal gene expression be can accomplish early, clinical carcinoma of the pancreas or real prognosis early diagnosis of large bowel cancer sufferer given.So just might implement the early diagnosis of carcinoma of the pancreas or large bowel cancer, man's prevention early, early treatment, might from the source, thoroughly effect a radical cure carcinoma of the pancreas or large bowel cancer foul disease.

[description of drawings]

Fig. 1 is a pancreatic cancer patient CA242 genetic expression picture in the embodiment of the invention.

Fig. 2 is a large intestine cancer patient CA242 genetic expression picture in the embodiment of the invention.

Fig. 3 is a normal people CA242 genetic expression picture in the embodiment of the invention.

[embodiment]

Below in conjunction with accompanying drawing the specific embodiment of the invention is elaborated.

Embodiment 1

A kind of hybridization in situ detection kit of CA242 gene comprises hybridization probe, marker, synergistic agent, and wherein, described hybridization probe sequence is shown in SEQ ID NO.1.The hybridization probe digoxigenin labeled.Other liquid and sample in the test kit are composed as follows:

Digestive system 100 μ l/ manage 1 pipe/box colourless transparent liquid

Protection liquid 100 μ l/ pipe 1 pipe/box colourless transparent liquid

Prehybridization solution 1300 μ l/ manage 2 pipe/box colourless transparent liquids

Justice hybridization solution 10 μ l/ pipe 1 pipe/box colourless transparent liquid

Antisense hybridization solution 10 μ l/ manage 1 pipe/box colourless transparent liquid

Confining liquid 1000 μ l/ manage 1 pipe/box colourless transparent liquid

Alkaline phosphatase enzyme antibody 1 μ l/ manages 1 pipe/box colourless transparent liquid

Developer A 175 μ l/ manage 1 pipe/box yellow liquid

Developer B 320 μ l/ manage 1 pipe/box colourless transparent liquid

Light yellow or the colourless transparent liquid of damping fluid I 10x 90ml/ bottle 1 bottle/box

Light yellow or the colourless transparent liquid of damping fluid II 10x 80ml/ bottle 1 bottle/box

Light yellow or the colourless transparent liquid of damping fluid III 10x 20m/ bottle 3 bottle/boxes

Light yellow or the colourless transparent liquid of damping fluid IV 10x 90ml/ bottle 1 bottle/box

Stationary liquid 90ml/ bottle 1 bottle/box colourless transparent liquid

6/box of positive control sample

Mentioned reagent composition explanation: (all reagent are available from SIGMA)

1, Digestive system: the 20mg/ml Proteinase K, the 100mg Proteinase K adds DEPC-H ₂O 5ml;

2, the glycine of protection liquid: 0.2g adds 1 * damping fluid I of 1ml;

3, prehybridization solution: 1 * damping fluid II7.5ml

50×D?3ml

10mg/ml?yest?t-RNA?750ul

11mg/ml?SALMON?TESTES?DNA?682ul

0.04M?EDTA?3ml

50％formamide?15ml

4, the bloking of confining liquid: 0.03g (buying from Roche Holding Ag) adds 1ml 1 * damping fluid III;

5,10x damping fluid I:(PH7.1-7.4)

NaCl?80g

Na ₂HPO ₄.12H ₂O 360g

KCl 2g

KH ₂PO ₄2g

Add tri-distilled water to 1l, and autoclaving;

6,10x damping fluid II:(PH7.0)

NaCl 175.3g

Trisodium Citrate 88.2g

Several of HCl

Add tri-distilled water to 1l, and autoclaving;

7, damping fluid III:(PH7.9)

Tris 121.1g

NaCl 87.66g

About HCl 60ml

Add tri-distilled water to 1l, and autoclaving;

8, damping fluid IV:

1M Tris-HCl (PH9.5): Tirs 121.1g adds about HCl 3ml, adds water 900ml, transfers PH to 9.5, adds water to 1l, and autoclaving;

1M NaCl:NaCl 58.44 adds water to 1l, and autoclaving;

0.5M MgCl ₂: 101.65g MgCl ₂.6H ₂O adds water to 1l, and autoclaving;

9, stationary liquid: Paraformaldehyde 96 40g adds 1 * damping fluid I to 1l, and heat (about 50-60 degree) is stirred to dissolving a little;

10, developer A:NBT 1g adds 70%DMF11.44ml;

11, developer B:BCIP 1g adds 100%DMF30ml.

Test kit of the present invention can many person-portions use or person-portion use.

Embodiment 2

A kind of CA242 gene hybridization in situ detection method and test kit thereof are used

One, sample disposal

1, with the centrifuge tube of 10ml, dress 4.5ml lymphocyte separation medium, again the 3ml anticoagulation is slowly added contain lymphocyte separation medium (blood: in centrifuge tube lymphocyte separation medium=1: 1.5), the centrifugal 10min of 2000r/min;

2, draw the middle layer white corpuscle to another centrifuge tube, in this pipe, add 1 * damping fluid I of about twice again, mixing, the centrifugal 10min of 1500g/min;

3, abandon supernatant. precipitation adds 1 * damping fluid I of about twice, mixing, the centrifugal 10min of 1500g/min;

4, abandon supernatant, and test tube mouth excess liquid is gone with the tissue suction.Again precipitation is made suspension, drop in push jack on the slide, seasoning.(hospital with good conditionsi can use the pelleter film-making.) 3ml blood, can do 4 slice, thin pieces;

5, with 40ml 4% stationary liquid, in glass jar, fixedly 30min uses 1 * damping fluid I to wash 5min again.Every cylinder can be put 16;

6, sample can be kept at-20 ℃, or continues to do experiment.

Two, reagent in the test kit is mixed with working concentration

1, with 10 * damping fluid I with tri-distilled water by being diluted to 1 * damping fluid I at 1: 10;

2, with 20 * damping fluid II with tri-distilled water by being diluted to 2 * damping fluid II at 1: 10;

By being diluted to 0.2 * damping fluid II at 1: 100; By being diluted to 0.1 * damping fluid II at 1: 200;

3, with 10 * damping fluid III with tri-distilled water by being diluted to 1 * damping fluid III at 1: 10;

4,10 * damping fluid IV with tri-distilled water by be diluted at 1: 10 * damping fluid IV (get 1#, 2#, each 10ml of 3#, add water to 100ml both can).

Three, experimental procedure:

1, gets two of every person's samples to be checked, two of (other two give over to check with) and positive control samples (test at every turn and do a pair of positive control);

2, in glass jar, add Digestive system (Digestive system 100ul adds 1 * damping fluid 199.9ml, is working concentration) 20ml.37 ℃ of water-bath preheatings 10 minutes.Put 16 slides into, handle 12min, use 1 * damping fluid I to wash 5min again for 37 ℃;

3, wash 10min with 0.2% protection liquid (protection liquid 1ml adds 1 * damping fluid I99ml and is working concentration), tri-distilled water is washed 5min, and above process is all carried out at glass jar.The slide seasoning;

4, slide is put into the box of preserving moisture, add prehybridization solution 20ul/ sheet. covered, the lid box of tightly preserving moisture is placed in 42 ℃ of constant water bath box more than the 3h;

5, take out slide, discard cover glass, slide is put into glass jar, with 70%, 90%, 95% ethanol is respectively washed 2min, seasoning;

6, slide is put into the box of preserving moisture, two of every patient specimens, one adds just hybridization solution 20ul/ sheet, and another adds antisense hybridization solution 20ul/ sheet, covered, the lid box of tightly preserving moisture is placed on 16-24h in 42 ℃ of constant water bath box;

7, take out slide, discard cover glass, slide is put into glass jar

In 42 ℃ of constant water bath box, wash twice, each 15min with 2 * damping fluid II

In 42 ℃ of constant water bath box, wash once each 15min with 0.2 * damping fluid II

In 42 ℃ of constant water bath box, wash twice, each 15min with 0.1 * damping fluid II;

8, wash 30s with 1 * damping fluid III, take out slide, seasoning;

9, slide is put into the box of preserving moisture, add 0.5%l confining liquid (the 1ml confining liquid adds 5ml 1 * damping fluid III) 100ul/ sheet, cover the box of tightly preserving moisture, at room temperature act on 30min;

10, take out slide, III washes 30s with 1 * damping fluid, seasoning;

11, slide is put into the box of preserving moisture, add alkaline phosphatase enzyme antibody (adding 1.8ml 1 * damping fluid III) 100ul/ sheet, cover the box of tightly preserving moisture and at room temperature act on 30min;

12, take out slide, wash 3 times, each 15min with 1 * damping fluid III;

13,1 * damping fluid IV washes 2min, adds developer (developer A73.3ul, developer B157.5ul are added among 30ml 1 * damping fluid IV, mixing), more than the room temperature lucifuge 12h;

14, wash 5min with tri-distilled water, seasoning, (add with glycerine 10% 1 * damping fluid I mixing) mounting microscopy.

Four, the result judges

100-300 cell of counting calculates the per-cent of catching the purple cell under light microscopic.

What the positive control sample added the antisense hybridization solution should catch purple more than 80%.

All add the negative internal reference of just hybridization solution should be colourless.

The cDNA of digoxigenin labeled, RNA and oligonucleotide probe, not only probe has a biotin labeling advantage, also having overcome biotin labeled probe is organized the endogenous vitamin H to do shortcomings such as sorrow in the crossover process in position), this hybridization probe and the leukocytic RNA nucleic acid to be measured of blood of human body are hybridized, method with immunohistochemical methods develops the color again, under light microscopic, observe existence and the location of mRNA,, judge the expression amount of goal gene according to painted cell count.

The inventive method is a nucleic acid hybridization in situ technology commonly used at present, and this method is used for determining by detecting the CA242 gene expression amount in the substrate cell whether carcinoma of the pancreas or large bowel cancer take place.Clinical study shows that the CA242 gene is the specific gene of carcinoma of the pancreas or large bowel cancer, because the CA242 gene is not expressed in the normal people, express in cancer only, illustrate that carcinoma of the pancreas or large bowel cancer take place, be used for determining whether carcinoma of the pancreas or large bowel cancer take place, or normal.Thereby obtain the diagnostic message of carcinoma of the pancreas or large bowel cancer.

The embodiment of the invention is sampled as: 5 of carcinoma of the pancreas patients, 5 of patients with colorectal cancer, 5 of normal control groups.Take out all people's to be checked peripheral blood 3-5 milliliter (separation white corpuscle) and do in situ hybridization.The result represents that all cancer patients CA242 genes have overexpression, cell dyeing; Normal control group CA242 gene is not expressed the cell dye-free.Concrete outcome is asked for an interview Fig. 1, Fig. 2 and Fig. 3.

Embodiment 3

Detect the carcinoma of the pancreas disease and detect parallel laboratory test between the carcinoma of the pancreas disease with the CA242 kit gene with the VEGF kit gene.

Specificity, susceptibility, accuracy for each comfortable carcinoma of the pancreas disease of scientific evaluation said gene.We use the method for parallel test, detect the mRNA of said gene simultaneously, detection technique adopts the nucleic acid hybridization in situ technology, with same routine carcinoma of the pancreas disease peripheral blood of patients, detect simultaneously CA242 gene and VEGF (VEGF gene order NM-001025366,6p12 " 3665bp cds:492 ... the 1730bp) mRNA of gene (carrying out same procedure and step and reagent that the hybridization in situ technique of embodiment 1 and embodiment 2 is all adopted in the numeration down of nucleic acid hybridization in situ, immunohistochemical staining, mirror, report as a result etc.).Find the CA242 gene in carcinoma of the pancreas disease patient expression amount than the expression amount height of VEGF gene same disease patient.The result shows that specificity, susceptibility, the accuracy of the medical diagnosis on disease of CA242 gene pairs carcinoma of the pancreas are better than VEGF gene, and in situ hybridization genetic expression figure shows that CA242 expression of gene amount is 70%, and VEGF expression of gene amount is 50%.The index that test kit of the present invention is done in the carcinoma of the pancreas medical diagnosis on disease has very important clinical meaning.

The above only is a preferred implementation of the present invention; should be pointed out that for those skilled in the art, under the prerequisite that does not break away from the inventive method; can also make some improvement and replenish, these improvement and replenish and also should be considered as protection scope of the present invention.

SEQUENCE?LISTING

＜110〉Rui bends biotechnology (Shanghai) Co., Ltd.

＜120〉a kind of hybridization in situ detection kit of CA242 gene and detection method thereof and application

<130>/

<160>1

<170>PatentIn?version?3.3

<210>1

<211>329

<212>DNA

＜213〉homo sapiens (Homo sapiens)

<400>1

gccataaagc?tgcagttaag?aaatttgtcg?cctggcaaca?ctaacgccag?ggtcacccgc 60

gttaaggtga?cggcccccca?caccatcaag?gccgacccgt?caggcgccac?tatcacaact 120

gccgctgcag?cccggttcat?ggccgacgtg?cgttggggct?taggcgtggc?tgaagatggt 180

gagattggcc?atggcattct?cggtgttttg?ttcaatctag?ctgatacagt?gctgggtggc 240

ctcccatcga?cactgctacg?tgcagcgagt?ggccagtaca?tgtacggccg?gcctgttggc 300

aatgccaacg?gtgagcccga?ggtaaaatt 329

Claims (10)

1. the application of the hybridization in situ detection kit of a CA242 gene in preparation detection carcinoma of the pancreas or large bowel cancer disease medicament, described test kit comprises hybridization probe, marker, described hybridization probe sequence is shown in SEQ ID NO.1.

2. application according to claim 1 is characterized in that: the RNA sequence of described hybridization probe sequence shown in SEQ ID NO.1.

3. application according to claim 1 and 2 is characterized in that: described marker is selected from radionuclide or non-radioactive marker.

4. application according to claim 3 is characterized in that: described radionuclide is selected from ³H, ³⁵S, ¹²⁵I or ³²A kind of among the P.

5. application according to claim 3 is characterized in that: described non-radioactive marker is selected from a kind of in vitamin H, digoxin, alkaline phosphatase, horseradish peroxidase or the fluorescein.

6. application according to claim 5 is characterized in that: described non-radioactive marker is preferably from digoxin.

7. application according to claim 1 and 2 is characterized in that: described test kit also comprises synergistic agent, and described synergistic agent is the alkaline phosphatase enzyme antibody.

8. the hybridization in situ detection kit of a CA242 gene comprises hybridization probe, marker, it is characterized in that, described hybridization probe sequence is shown in SEQ ID NO.1, and described marker is selected from radionuclide or non-radioactive marker.

9. the in situ hybridization detection method of a CA242 gene is characterized in that, this method may further comprise the steps:

A, the hybridization probe in the described test kit of claim 8 is contacted with RNA to be measured in the substrate, form hybridization complex;

The hybridization complex that b, detection a step obtain.

10. detection method according to claim 9 is characterized in that: the condition that forms hybridization complex in a step is: the temperature of nucleic acid hybridization is 42 ℃; The time of nucleic acid hybridization is 16-24 hour, and described substrate is selected blood cell sample or histocyte sample for use.

Images